share_log

康希諾生物：截至2024年9月30日止九個月的第三季度報告

CANSINOBIO: THIRD QUARTERLY REPORT FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2024

HKEX ·  Oct 29, 2024 02:32

Summary by Moomoo AI

康希诺生物於2024年9月30日公布了最新財務報告。報告顯示，公司總收入達到567,077,966.63元，較去年同期增長222.88%，淨利潤為263,646,520.16元，年增率為76.09%。然而，公司同時報告了總支出的增加，導致淨利潤較上一年度有所下降。公司股東名單中，HKSCC NOMINEES LIMITED持股比例最高，達到39.56%。公司董事長兼首席執行官Xuefeng YU於2024年10月29日確認了財務報告的準確性。康希诺生物的財務狀況顯示出強勁的收入增長，但也面臨著成本控制的挑戰。
康希诺生物於2024年9月30日公布了最新財務報告。報告顯示，公司總收入達到567,077,966.63元，較去年同期增長222.88%，淨利潤為263,646,520.16元，年增率為76.09%。然而，公司同時報告了總支出的增加，導致淨利潤較上一年度有所下降。公司股東名單中，HKSCC NOMINEES LIMITED持股比例最高，達到39.56%。公司董事長兼首席執行官Xuefeng YU於2024年10月29日確認了財務報告的準確性。康希诺生物的財務狀況顯示出強勁的收入增長，但也面臨著成本控制的挑戰。
Kangxinuo Biotechnology announced its latest financial report on September 30, 2024. The report shows that the company's total revenue reached 567,077,966.63 yuan, an increase of 222.88% compared to the same period last year, with a net profit of 263,646,520.16 yuan, a year-on-year growth rate of 76.09%. However, the company also reported an increase in total expenses, resulting in a decrease in net profit compared to the previous year. The shareholder with the highest ownership in the company's shareholder list is HKSCC NOMINEES LIMITED, reaching 39.56%. Chairman and CEO Xuefeng YU confirmed the accuracy of the financial report on October 29, 2024. Kangxinuo Biotechnology's financial situation shows strong revenue growth, but also faces challenges in cost control.
Kangxinuo Biotechnology announced its latest financial report on September 30, 2024. The report shows that the company's total revenue reached 567,077,966.63 yuan, an increase of 222.88% compared to the same period last year, with a net profit of 263,646,520.16 yuan, a year-on-year growth rate of 76.09%. However, the company also reported an increase in total expenses, resulting in a decrease in net profit compared to the previous year. The shareholder with the highest ownership in the company's shareholder list is HKSCC NOMINEES LIMITED, reaching 39.56%. Chairman and CEO Xuefeng YU confirmed the accuracy of the financial report on October 29, 2024. Kangxinuo Biotechnology's financial situation shows strong revenue growth, but also faces challenges in cost control.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Related Stocks Related Stocks
    Symbol Mini Chart Price
    VIVA BIOTECH
    01873
    -- 1.320
    INNOCARE
    09969
    -- 6.540
    HUA MEDICINE-B
    02552
    -- 1.670
    TIGERMED
    03347
    -- 32.200
    LEPU BIO-B
    02157
    -- 3.110
    Log In for the Full List
    Reassessing Chinese Assets
    Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.
    Discussing
    Tesla's earnings caused fluctuations, what's your market outlook？
    Tesla's Q4 2024 revenue was $25.71 billion, up 2% year-on-year but below expectations. Can Tesla's stock price keep rising in 2025 with Trum Show More
    TSLA earnings preview: Grab rewards by guessing the opening price!